This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing the FDA expanded label for ENTYVIO® (vedolizumab) for subcutaneous (SC) administration maintenance therapy in adults with moderately to severely active Crohn’s Disease.

Ticker(s): TAK

Who's the expert?

Institution: Digestive Disease Clinic

  • Gastroenterologist in practice for over 15 years
  • treats 20-25 active UC patients in his practice.

Interview Goal
To discuss the FDA expanded label for ENTYVIO® (vedolizumab) for subcutaneous (SC) administration maintenance therapy in adults with moderately to severely active Crohn’s Disease.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.